.Pharmacolibrary.Drugs.N_NervousSystem.N07B_DrugsUsedInAddictiveDisorders.N07BB05_Nalmefene.Nalmefene .Pharmacolibrary.Drugs.N_NervousSystem.N07B_DrugsUsedInAddictiveDisorders.N07BB05_Nalmefene.Nalmefene| name: | Nalmefene |
| ATC code: | N07BB05 | route: | oral |
| n-compartments | 2 |
Nalmefene is an opioid receptor modulator, primarily used to reduce alcohol consumption in adults with alcohol dependence. It acts as an antagonist at the mu and delta opioid receptors and a partial agonist at the kappa opioid receptor. It is approved in several countries (e.g., in the EU) as a prescription medication for the reduction of alcohol consumption in patients with alcohol dependence.
Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.
Kyhl, LE, et al., & Areberg, J (2016). Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. British journal of clinical pharmacology 81(2) 290–300. DOI:10.1111/bcp.12805 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26483076
Palpacuer, C, et al., & Naudet, F (2015). Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials. PLoS medicine 12(12) e1001924–None. DOI:10.1371/journal.pmed.1001924 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26694529